Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2.
Petersen
Karl-Uwe
KU
Institute of Pharmacology and Toxicology, Rheinisch-Westfälische Technische Hochschule Aachen, Germany. KarlUwe.Petersen@post.rwth-aachen.de
D000328:Adult; D000368:Aged; D019540:Area Under Curve; D001682:Biological Availability; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007333:Insulin Resistance; D007774:Lactation / Q000502:physiology; D008099:Liver / Q000378:metabolism; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011247:Pregnancy; D000077154:Rosiglitazone; D013607:Tablets; D045162:Thiazolidinediones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D004338:Drug Combinations; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D000077154:Rosiglitazone; D013607:Tablets; D045162:Thiazolidinediones